Role of Surgery in Treatment of Locally Advanced Prostate Cancer
Authors:
D. Prezioso; R. Galasso; M. Di Martino; G. Iapica; F. Iacono
Authors place of work:
Department of Urology, Frederico II University, Neapol, Itálie
Published in the journal:
Urol List 2007; 5(4): 30-36
Summary
The proportion of prostate cancer diagnosed at localized stages increased from 56.7% to 74.0% between 1973 and 1993 (“stage migration”). A corresponding increase in the number of radical prostatectomies performed each year was also noted. Nomograms are mathematical algorithms derived from statistical models that are used to predict outcomes for an individual patient, or for groups of patients. In fact, careful pre-operative patient and tumor selection before radical prostatectomy is mandatory. Locally advanced prostate cancer is defined as tumor that has extended clinically beyond the prostatic capsule, with invasion of the pericapsular tissue, apex, bladder neck or seminal vescicle, but without lymph node involvement or distant metastasis. It is estimated that 12-15% of prostate cancer are stage T3. Overstaging or understaging of this cancer is common. Correct staging of clinical T3 disease is even more difficult and both overstaging pT2 and understaging pT4 or pN+ are common. The goals of treatment for T3 tumors are to cure the disease, prolong survival or metastasisfree survival and improve the quality of life. The authors reviewed the most important studies, investigated radical prostatectomy as monotherapy for locally advanced prostate cancer and the integration of surgery with hormonal treatment. The EAU guidelines on prostate cancer state that radical prostatectomy in locally advanced disease is an option for selected patients with small T3, PSA <20 ng/ml, Gleason score <8 and a life expectancy >10 years. Ten to 15% of clinical T3 are overstaged as pT2. This may lead to the possibility of curing these patients with surgery as monotherapy. The increased use of nomograms and increased knowledge of recognized prognostic factors could lead to the selection of a large number of patients, often with a long life expectancy, who couldbenefit from surgical treatment.
Key words:
radical prostatectomy, locally advanced prostate cancer, surgical treatment, review
Zdroje
1. Mettlin CJ and Murphy GP: Why is the prostate cancer death rate declining in the United States? Cancer 82: 249-251, 1997.
2. Sheikh S and Bullock C: Rise and fall of radical prostatectomy rates from 1989 to 1996. Urology 59: 378-382, 2002.
3. Hull GW, Rabbani F, Abbas F, Wheeler TM, Kattan MW and Scardino PT: Cancer control with radical prostatectomy alone in 1,000 consecutive patients. J Urol 167: 528, 2002.
4. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE et al: Combination of PSA, clinical stage and Gleason score to predict pathological stage of localized prostate cancer, a multiinstitutional update. JAMA 277: 1445, 1997.
5. Zagars GK, Pollack A and Von Eschenback AC: Prognostic factors for clinically localized prostate carcinoma: analysis of 938 patients irradiated in the PSA era. Cancer 79: 1370, 1997.
6. Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z and Leibel SA: Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol 18: 3352, 2000.
7. Kattan MW, Eastham JA, stapleton AM, Wheeler TM and Scardino PT: A pre-operative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90: 766, 1998.
8. Graefen M, Noldus J, Pichlmeier U, Haese A, Hammerer PG, Fernandez S et al: Early PSA relapse after radical retropubic prostatectomy: prediction on the basis of preoperative tumor characteristics. Eur Urol 36: 21-30, 1999.
9. Graefen M, Haese A, Pichlmeier U, Hammerer PG, Noldus J, Butz K et al: A validated strategy for side specific prediction of organ confined prostate cancer: a tool to select for nerve sparing radical prostatectomy. J Urol 165: 857-863, 2001.
10. Quinn DI, Henshall SM, Haynes AM, Brenner PC, Kooner R, Golovsky D et al: Prognostic significance of pathologic features in localized prostate cancer treated with radical prostatectomy: implication for staging systems and predictive models. J Clin Oncol 19: 3692-3705, 2001.
11. Babaian RJ, Troncoso P, Bhadkamkar VA and Johnston DA: Analysis of clinicopathologic factors predicting outcome after radical prostatectomy. Cancer 91: 1414-1422, 2001.
12. Stamey TA, Villers AA, McNeal JE, Link PC and Freiha FS: Positive surgical margins at radical prostatectomy: importance of the apical dissection. J Urol 143: 1166, 1990.
13. van den Ouden D, Bentvelsen FM, Boeve ER and Schroeder FH: Positive margins after radical prostatectomy: correlation with local recurrence and distant progression. Br J Urol 72: 489, 1993.
14. Zietman AL, Edelstein RA, Coen JJ, Babayan RK and Krane RJ: Radical prostatectomy for adenocarcinoma of the prostate: the influence of preoperative and pathologic findings on biochemical disease-free outcome. Urology 43: 828, 1993.
15. Zincke H, Oesterling JE, Blute ML, Bergstralh EJ, Myers RP and Barrett DM: Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer. J Urol 154: 1850, 1994.
16. Trapasso JG, Dekernion JB, Smith RB and Dorey F: The incidence and significance of detectable levels of serum PSA after radical prostatectomy. J Urol 152: 1821, 1994.
17. Catalona WJ and Smith DS: Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results. J Urol 160: 2428, 1998.
18. Pound CR, Partin AW, Epstein JI and Walsh PC: PSA after anatomic radical retropubic prostatectomy. Patterns of recurrence and cancer control. Urol Clin North Am 24: 395, 1997.
19. Kattan MW, Wheeler TM and Scardino PT: Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer. J Clin Oncol 17: 1499, 1999.
20. Pound CR, Partin AW, Eisenberger MA, Chan DW, Pearson JD and Walsh PC: Natural history of progression after PSA elevation following radical prostatectomy. JAMA 281: 1591, 1999.
21. Ornstein DK, Oh J, Herschman JD and Andriole GL: Evaluation and management of the man who has failed primary curative therapy for prostate cancer. Urol Clin North Am 25: 591, 1998.
22. Boccon-Gobod L, Bertaccini A, Bono A, Dev Sarmah B, Holtl W, Mottet N et al: Management of locally advanced prostate cancer: a European consensus. Int J Clin Pract 57(3): 187-194, 2003.
23. Sullivan LD: Controversies in the management of clinical T3 carcinoma of the prostate. Can J Urol 1(3): 39-48, 1994.
24. van den Ouden D and Schroeder FH: Management of locally advanced prostate cancer. World J Urol 18: 194-203, 2000.
25. Morgan WR, Bergstralh EJ and Zincke H: Long-term evaluation of radical prostatectomy as treatment in clinical stage C (T3) prostate cancer. Urology 41(2): 113-120, 1993.
26. Ward JF, Slezak JM, Blute ML, Bergstralh EJ and Zincke H: radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of PSA testing: 15-year outcome. BJU Int 95(6): 751-756, 2005.
27. Allison RR, Schulsinger A, Vongtama V, Grant P, Shin KH and Huben R: If you „watch and wait“, prostate cancer may progress dramatically. Int J Radiat Oncol Biol Phys 39(5): 1019-1023, 1997.
28. Perez CA, Hanks GE, Leibel SA, Zietman AL, Fuks Z and Lee WR: Localized carcinoma of the prostate (stage T1B, T2 and T3). Review of management with external beam radiation therapy. Cancer 72(11): 3156-3173, 1993.
29. Arcangeli G, Micheli A, Arcangeli G, Pansadoro V, De paula F, Giannarelli D et al: Definitive radiation therapy for localized prostate adenocarcinoma. Int J Radiat Oncol Biol Phys 20(3): 439-446, 1991.
30. Goluboff ET and Benson MC: External beam radiation therapy does not offer long-term control of prostate cancer. Urol Clin N Am 23: 617, 1996.
31. Lawton CA, Winter K, Murray K, Machtay M, Mesic JB, Hanks GE et al: Update results of tha phase III radiation therapy oncology group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavourable prognosis carcinoma of the prostate. Int J Radiat Oncol Biol Phys 49(4): 937-946, 2001.
32. Bolla M, Collette L, Blank L, Warde P et al: Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomized trial. Lancet 360: 103-108, 2002.
33. van den Ouden D, Bentvelsen FM, Boevč ER and Schroeder FH: Positive margins after radical prostatectomy: correlation with local recurrence and distant progression. Br J Urol 72: 489, 1993.
34. Aus G, Abbou CC, Pacik D, Schmid HP, Van Poppel H, Wolff JM et al: EAU working group on oncological urology. EAU Guidelines on prostate cancer. Eur Urol 40: 97-101, 2001.
35. Lerner SE, Blute ML and Zincke H: Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J Urol 154: 1447, 1995.
36. Reiner WG and Walsh PC: An anatomical approch to the surgical management of the dorsal vein and Santorini’s during radical retropublic surgery. J Urol 121(2): 198-200, 1979.
37. van den Ouden D, Davidson PJT, Hop W and Schroder FH: Radical prostatectomy as monotherapy for locally advanced (stage T3) prostate cancer. J Urol 151: 646, 1994.
38. Gerber GS, Thisted RA, Chodak GW, Shroder FH, Frohmuller HGW, Scardino PT et al: Results of radical prostatectomy in men with locally advanced prostate cancer: multi-institution pooled analysis. Eur Urol 32: 385-390, 1997.
39. van den Ouden D, Hop WCJ and Schroder FH: Progression in and survival of patients with locally advanced prostate cancer (T3) treated with radical prostatectomy as monotherapy. J Urol 160: 1392-1397, 1998.
40. Schmid HP, mihatsch MJ, Hering F and Rutishauser G: Impact of minimal lymph node metastasis on long-term prognosis after radical prostatectomy. Eur Urol 31: 11, 1997.
41. Van Poppel H, Goethuys H, Callewaert P, Vanuytsel L, Van de Voorde W and Baert L: Radical prostatectomy can provide a cure for well-selected clinical stage T3 prostate cancer. Eur Urol 38: 372-379, 2000.
42. Martinez de la Riva SI, Lopez-Tomasety JB, Dominguez RM, Cruz EA and Blanco PS: Radical prostatectomy as monotherapy for locally advanced prostate cancer (T3a): 12 years follow-up. Arch Esp Urol 57(7): 679-692, 2004.
43. Syrigos KN, Karapanagiotou E and Harrington KJ: Prostate cancer in the elderly. Anticancer Res 25: 4527-4534, 2005.
44. Lu-Yao GL, Potosky AL, Albertsen PC et al: Follow-up prostate cancer treatments after radical prostatectomy: a population based study. J Natl Cancar Inst 88: 166-172, 1996.
45. Christopher K, Payne I, Joseph W et al: Genitourinary problems in the elderly. Surg Clin N Am 74: 401-407, 1994.
46. Iselin CE, Robertson JE and Paulson DF: Radical peneat prostatectomy: oncological outcome during a 20-year period. J Urol 161: 163, 1999.
47. Prezioso D, Lotti T, Polito M and Montironi R: Neoadjuvant hormone treatment with leuprolide acetate depot 3.75 mg and cyproterone acetate, before radical prostatectomy: a randomized study. Urol Int 72(3): 189-195, 2004.
48. Witjes WP, Schulman CC and Debruyne FM: Preliminary results of a prospective randomized study comparing radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostate carcinoma. Urology 49: 65, 1997.
49.Cookson MS, Sogani PC, Russo P, Sheinfeld J, Herr H, Dalbagni G, Reuter VE, Begg CB and Fair WR: Pathological staging and biochemical recurrence after neoadjuvant androgen deprivation therapy in combination with radical prostatectomy. Br J Urol 79(3): 432-38, 1997.
50. Soloway MS, Pareek K, Sharifi R, Wajsman Z, McLeod D and Wood DP: The Lupron Depot Neoadjuvant Prostate Cancer Study Group. Neoadjuvant androgen ablation before radical prostatectomy in cT2bN0M0 prostate cancer: 5 year results. J Urol 167: 112, 2002.
51. Fair WR, Cookson MS, Stroumbakis N, Cohen D, Aprikian AG, Wang Y: The indication, rationale and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology 49: 46, 1997.
52. Van Poppel H, De Ridder D, Elgamal AA, Van De Voorde W, Werbrouk P and Ackaert K: Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgium Uro-Oncological Study Group. J Urol 154: 429, 1995.
53. Schulman CC, Debruyne FM, Forster G, Selvaggi FP, Zlotta AR and Witjes WP: 4 year follow up results of a European prospective randomized study on neoadjuvant hormonal therapy prior to radical prostatectomy in T2-3N0M0 prostate cancer: European Study Group on Neoadjuvant Treatment of Prostate Cancer. Eur Urol 38: 706, 2000.
54. Klotz LH, Goldenberg SL, Jewitt M, Barkin J, Chetner M and Fradet Y: CUOG randomized trial of neoadjuvant androgen ablation before radical prostatectomy: 36 month post-treatment PSA results: Canadian Urologic Oncology Group. Urology 53: 757, 1999.
55. Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F and Klotz LH: The Canadian Uro-Oncology Group. Randomized comparative study of 3 vs. 8 months neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 166: 500, 2001.
56. Gleave ME et al: Randomized comparative study of 3 vs. 8 months of neoadjuvant hormonal therapy prior to radical prostatectomy: 3 year PSA recurrence rates. J Urol 169: 179, 2003.
57. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP and Puras-Baez A: Randomized prospective study comparing radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 154: 424, 1995.
58. Goldenberg SL, Klotz LH, Srigley J, Jewett MA, Mador D and Fradet Y: Randomized, prospective, controlled study comparing radical prostatectomy alone and in neoadjuvant androgen withdrawal in the treatment of localized prostate cancer. Canadian Urological Oncology Group. J Urol 156: 873, 1996.
59. Witjes WP, Schulman CC and Debruyne FM: Preliminary results of a prospective randomized study comparing radical prostatectomy associated with neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostate carcinoma. Urology 49: 65, 1997.
60. Bazinet M, Zheng W, Begin LR, Aprikian AG, Karakiewicz PI and Elhilali MM: Morphologic changes induced by neoadjuvant androgen ablation may result in underdetection of positive surgical margins and capsular involvement by prostatic adenocarcinoma. Urology 49: 721, 1997.
61. Powell IJ, Tangen CM, Miller GJ, Lowe BA, Haas G, Carroll PR, Osswald MB, DeVere White R, Thompson IM Jr and Crawford ED: Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5 years follow up, phase II Southwest Oncology Group (SWOG) study 9109. J Urol 168: 2016-19, 2002.
62.Schow DA, Renfer LG, Rozanski TA and Thompson IM: Prevalence of hot flushes during and after neoadjuvant hormonal therapy for localized prostate cancer. South Med J 91: 855, 1998.
63. Schulman CC and Sassine AM: Neoadjuvant hormonal deprivation before radical prostatectomy. Clin Invest Med 16: 523, 1993.
64. Witjes WP, Schulman CC and Debruyne FM: Preliminary results of a prospective randomized study comparing radical prostatectomy associated wiyh neoadjuvant hormonal combination therapy in T2-3 N0 M0 prostate carcinoma. Urology 49: 65, 1997.
65. Debruyne FM, Witjes WP, Schulman CC, van Chang PJ and Oosterhof GO: A multicentre trial of combined neoadjuvant androgen blockade with Zoladex and flutamide prior to radical prostatectomy in prostate cancer. Tha European Study Group on Neoadjuvant Treatment. Eur Urol 26(suppl 1): 4, 1994.
66. Van Poppel H, De Ridder D, Elgamal AA, Van De Voorde W, Werbrouk P and Ackaert K: Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. The Belgium Uro-Oncological Study Group. J Urol 154: 429, 1995.
67. Fair WR, Cookson MS, Stroumbakis N, Cohen D, Aprikian AG and Wang Y: The indication, rationale and results of neoadjuvant androgen deprivation in the treatment of prostatic cancer: Memorial Sloan-Kettering Cancer Center results. Urology 49: 46, 1997.
68. Amling CL, Leibovich BC, Lerner SE, Bergstralh EJ, Blute ML, Myers RP et al: Primary surgical therapy for clinical T3 adenocarcinoma of the prostate. Semin Urol Oncol 15(4): 215- 221, 1997.
69. The Veterans Administration Co-operative Urological Research Group: Treatment and survival of patients with cancer of the prostate. Surg Gynecol Obstet 124: 1011-1017, 1967.
70. Messing EM, Manola J, Sarosdy M et al: Immediate hormonal therapy vs. observation after radical prostatectomy and pelvic lymphadenectomy for node positive prostate cancer: at 10 years results of EST3886. Proc ASCO 22: 399s, 2004.
71. Choo R, Hruby G, Hong J, Hong E, DeBoer G, Danjoux C et al: Positive resection margin and/or pathologic T3 adenocarcinoma of prostate with undetectable postoperative PSA after radical prostatectomy: to irradiate or not? Int J Radiat Oncol Biol Phys 52(3): 674-680, 2002.
72. Bolla M, Van poppel H, Van Chang P, Vekemans K, Rigatti P, De Reijke T et al: Does post-operative radiotherapy after radical prostatectomy improve progression free survival in pT3 N0 prostate cancer? American Society of Clinical Oncology: Annual meeting proceedings 23: 382, 2004.
73. Dominique S and Ravery V: Pre-operative imaging studies is there any necessity? EAU Update Series 3: 72-76, 2005.
74. Cornud F, Hamida K, Flam T, Helenon O, Chertien Y, Thiounn N et al: Endorectal color Doppler sonography and endorectal MR imaging features of nonpalpable prostate cancer: correlation with radical prostatectomy findings. AJR Am J Roentgenol 175(4): 1161-1168, 2000.
75. Wang L, Mullerad M, Chen HN, Eberhardt SC, Kattan MW, Scardino PT et al: Prostate cancer: incremental value of endorectal MR imaging findings for prediction of extracapsular extension. Radiology 232(1): 133-139, 2004.
76. Yu KK, Sheidler J, Hricak H, Vigneron DB, Yu KK, Sokolov DL et al: Prostate cancer: localization with three-dimensional proton MR spectroscopic imaging-clinicopathologic study. Radiology 213(2): 473-480, 1999.
77. Harisinghani MG, Barentsz J, Hann PF, Deserno WM, Tabatabaei S, van de Kaa CH et al: Non invasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med 348(25): 2491-2499, 2003.
78. Reckwits T, Potter SR and Partin AW: Prediction of
locoregional extension and metastatic disease in prostate cancer: a review. World J Urol 18(3): 165-172, 2000.
Štítky
Paediatric urologist UrologyČlánok vyšiel v časopise
Urological Journal
2007 Číslo 4
Najčítanejšie v tomto čísle
- Whats new about PSMA (Prostate-specific membrane antigen): urologist´s point of view
- Transrectal ultrasonography guided prostate needle biopsy
- Current methods of nephroureteroctomy
- Role of Surgery in Treatment of Locally Advanced Prostate Cancer